The invention provides a pharmaceutical composition comprising a human interleukin (IL)-3-diphtheria toxin conjugate for use in a method for treating a plasmacytoid dendritic cell cancer in a human, wherein said method comprises administering said human IL-3-diphtheria toxin conjugate to said human.